Spark vet Furey steering Imvax into glioblastoma Phase II with $112M series C

A $112 million series C round will help Imvax move its autologous neoantigen immunotherapy into Phase II testing for glioblastoma. The therapy, which CEO John Furey told BioCentury is first in class, uses a patient’s own tumor cells to trigger a personalized immune system attack against a brain tumor.

Imvax Inc. was founded in 2016 by David Andrews and Arthur Howe with a license to the immunotherapy technology from Thomas Jefferson University, where Andrews is a professor. He is CMO of Imvax; Howe, who serves as CFO, co-founded and served as chairman and CEO of tech company Verve Group...